Follicular lymphoma patients with a high FLIPI score and a high tumor burden: A risk stratification model
Abstract
Background/Aim. The widely accepted Follicular Lymphoma International Prognostic Index (FLIPI) divides patients into three risk groups based on the score of adverse prognostic factors. The estimated 5-year survival in patients with a high FLIPI score is around 50%. The aim of this study was to analyse the prognostic value of clinical and laboratory parameters that are not included in the FLIPI and the New Prognostic Index for Follicular Lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project (FLIPI2) indices, in follicular lymphoma (FL) patients with a high FLIPI score and high tumor burden. Methods. The retrospective analysis included 57 newly diagnosed patients with FL, a high FLIPI score and a high tumor burden. All the patients were diagnosed and treated between April 2000 and June 2007 at the Clinic for Hematology, Clinical Center of Serbia, Belgrade. Results. The patients with a histological grade > 1, erythrocyte sedimentation rate (ESR) ≥ 45 mm/h and hypoalbuminemia had a significantly worse overall survival (p = 0.015; p = 0.001; p = 0.008, respectively), while there was a tendency toward worse overall survival in the patients with an Eastern Cooperative Oncology Group (ECOG) > 1 (p = 0.075). Multivariate Cox regression analysis identified a histological grade > 1, ESR ≥ 45 mm/h and hypoalbuminemia as independent risk factors for a poor outcome. Based on a cumulative score of unfavourable prognostic factors, patients who had 0 or 1 unfavourable factors had a significantly better 5-year overall survival compared to patients with 2 or 3 risk factors (75% vs 24.1%, p = 0.000). Conclusion. The obtained results suggest that from the examined prognostic parameters histological grade > 1, ESR ≥ 45 mm/h and hypoalbuminemia can contribute in defining patients who need more aggressive initial treatment approach, if two or three of these parameters are present on presentation
References
The Non-Hodgkin Lymphoma Classification Project. A clini-cal evaluation of the international lymphoma study group clas-sification of non-Hodgkin's lymphoma. Blood 1997; 89(11): 3309−18.
Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Forstpointner R, et al. Treatment strategies in follicular lympho-mas: current status and future perspectives. J Clin Oncol 2005; 23(26): 6394−9.
Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, Devita VT Jr. The treatment of indolent lymphomas: watchful waiting vs aggressive combined modality treatment. Semin Hematol 1988; 25(Suppl 2): 11−6.
Peterson BA, Petroni GR, Frizzera G, Barcos M, Bloomfield CD, Nissen NI, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol 2003; 21(1): 5−15.
Horning SJ, Rosenberg SA. The natural history of initially un-treated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311(23): 1471−5.
Apostolidis J, Gupta RK, Grenzelias D, Johnson PW, Pappa VI, Summers KE, et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 2000; 18(3): 527−36.
Horning SJ, Negrin RS, Hoppe RT, Rosenberg SA, Chao NJ, Long GD, et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 2001; 97(2): 404−9.
Rohatiner AZ, Gregory WM, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A, et al. Lister TA. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005; 23(10): 2215−23.
McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of pa-tients respond to a four-dose treatment program. J Clin Oncol 1998; 16(8): 2825−33.
Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma com-pared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106(12): 3725−32.
Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, et al. Phase III study of R-CVP compared with cyc-lophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26(28): 4579−86.
Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon main-tenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25(15): 1986−92.
Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi J, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112(13): 4824−31.
Siddhartha G, Vijay P. R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature. J Hematol Oncol 2009; 2(1): 14.
Leonard RC, Hayward RL, Prescott RJ, Wang JX. The identifica-tion of discrete prognostic groups in low grade non-Hodgkin's lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party. Ann Oncol 1991; 2(9): 655−62.
Romaguera JE, McLaughlin P, North L, Dixon D, Silvermintz KB, Garnsey LA, et al. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J Clin Oncol 1991; 9(5): 762−9.
Decaudin D, Lepage E, Brousse N, Brice P, Harousseau JL, Belhadj K, et al. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients--a study of the groupe d'Etude des lymphomes de l'Adulte. J Clin Oncol 1999; 17(8): 2499−505.
Federico M, Vitolo U, Zinzani PL, Chisesi T, Clò V, Bellesi G, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000; 95(3): 783−9.
Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic in-dex. Blood 2004; 104(5): 1258−65.
Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma de-veloped by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009; 27(27): 4555−62.
Swerdlow SH. International Agency for Research on Cancer; WHO classification of tumours of haematopoietic and lym-phoid tissues World Health Organization. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008.
Mann RB, Berard CW. Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method. Hematol Oncol 1983; 1(2): 187−92.
Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicu-lar lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l’Adulte (GELA). Blood 2006; 108(8): 2540−4.
Soubeyran P, Eghbali H, Bonichon F, Trojani M, Richaud P, Hoerni B. Low-grade follicular lymphomas: analysis of prognosis in a series of 281 patients. Eur J Cancer 1991; 27(12): 1606−13.
Federico M, Guglielmi C, Luminari S, Mammi C, Marcheselli L, Gia-nelli U, et al. Prognostic relevance of serum beta2 microglobu-lin in patients with follicular lymphoma treated with anthracyc-line-containing regimens. A GISL study. Haematologica 2007; 92(11): 1482−8.
Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351(21): 2159−69.
Glas AM, Kersten MJ, Delahaye LJM, Witteveen AT, Kibbelaar RE, Velds A, et al. Gene expression profiling in follicular lympho-ma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005; 105(1): 301−7.
Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent pre-dictor of survival in follicular lymphoma (FL). Blood 2005; 106(6): 2169−74.
Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008; 26(3): 440−6.
Martin AR, Weisenburger DD, Chan WC, Ruby EI, Anderson JR, Vose JM, et al. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 1995; 85(12): 3671−8.
Ott G, Katzenberger T, Lohr A, Kindelberger S, Rudiger T, Wilhelm M, et al. Cytomorphologic, immunohistochemical, and cytoge-netic profiles of follicular lymphoma: 2 types of follicular lym-phoma grade. Blood 2002; 99: 3806−12.
Hans CP, Weisenburger DD, Vose JM, Hock LM, Lynch JC, Aoun P, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003; 101(6): 2363−7.
Rohatiner AZ, Johnson PW, Price CG, Arnott SJ, Amess JA, Norton AJ, et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994; 12(6): 1177−84.
Deconinck E, Foussard C, Milpied N, Bertrand P, Michenet P, Cornil-let-LeFebvre P, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based che-motherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 2005; 105(10): 3817−23.
Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004; 104(9): 2667−74.
Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE, et al. High-dose therapy improves progression-free sur-vival and survival in relapsed follicular non-Hodgkin's lym-phoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21(21): 3918−27.
Sebban C, Brice P, Delarue R, Haioun C, Souleau B, Mounier N, et al. Impact of rituximab and/or high-dose therapy with auto-transplant at time of relapse in patients with follicular lym-phoma: a GELA study. J Clin Oncol 2008; 26(21): 3614−20.
Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at di-agnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008; 111(8): 4004−13.
van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, Bishop MR, et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998; 92(5): 1832−6.
Forrest DL, Thompson K, Nevill TJ, Couban S, Fernandez LA. Al-logeneic hematopoietic stem cell transplantation for progres-sive follicular lymphoma. Bone Marrow Transplant 2002; 29(12): 973−8.
Hosing C, Saliba RM, McLaughlin P, Andersson B, Rodriguez MA, Fayad L, et al. Long-term results favor allogeneic over auto-logous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol 2003; 14(5): 737−44.
Peniket AJ, de Ruiz EM, Taghipour G, Cordonnier C, Gluckman E, de Witte T, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31(8): 667−78.
Heinzelmann F, Ottinger H, Engelhard M, Soekler M, Bamberg M, Weinmann M. Advanced-Stage III/IV Follicular Lymphoma Treatment Strategies for Individual Patients. Strahlenther On-kol 2010; 186(5): 247−54.
Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111(12): 5530−6.
Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104(13): 3865−71.
Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, et al.. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yt-trium 90 ibritumomab tiuxetan. Cancer 2007; 109(9): 1804−10.
